Every Form 4 that Acadia Pharmaceuticals Inc. (ACAD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACAD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACAD filings page.
ACADIA Pharmaceuticals’ EVP and CFO Mark C. Schneyer exercised stock options covering 20,141 shares of common stock at an exercise price of $17.84 per share on August 5–6, 2026.
He then sold 20,141 shares in market transactions at prices around $29 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025.
ACADIA Pharmaceuticals executive Elizabeth H.Z. Thompson, EVP and Head of Research & Development, reported vesting and conversion of 32,272 restricted stock units into common stock on July 29, 2026. To cover withholding taxes on this vesting, she sold 16,558 shares of common stock on July 30, 2026 at prices around $26.13–$26.17 per share in mandatory transactions intended to comply with Rule 10b5-1(c) requirements. The RSU award vests 50% on July 29, 2026 and 25% on each of July 29, 2027 and July 29, 2028.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara sold 11,421 shares of common stock in an open-market transaction at a weighted average price of $26.0846 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, and Kihara now holds 13,088 shares directly.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
ACADIA PHARMACEUTICALS INC reported equity compensation grants linked to Baker-related entities and funds. The filing shows awards connected to board service by Julian C. Baker and Dr. Stephen R. Biggar, where the Baker funds have an indirect pecuniary interest.
The grants include a total of 18,622 restricted stock units and 32,008 non-qualified stock options, reported for the funds because each fund has an indirect pecuniary interest in these securities. The stock options carry a strike price of $21.66, vest in four equal quarterly installments beginning on May 29, 2026, and expire on May 28, 2036. The adviser has voting and dispositive power over the options, RSUs, and any common stock issued from them, while Julian C. Baker, Felix J. Baker, Baker Bros. Advisors LP, and its general partner disclaim beneficial ownership except to the extent of their pecuniary interest.
ACADIA Pharmaceuticals director Edmund Harrigan reported compensation-related equity activity, not open-market trading. On May 29, 2026, he exercised restricted stock units into 8,107 shares of common stock, bringing his direct common stock holdings to 43,148 shares.
He also received new awards on the same date: 9,311 restricted stock units, each representing a right to one share of common stock, and 16,004 director stock options with a $21.66 exercise price expiring on May 28, 2036. The new RSUs and options vest over roughly one year or until the next annual stockholders’ meeting, aligning his compensation with shareholder outcomes.
ACADIA PHARMACEUTICALS INC director Adora Ndu reported equity compensation activity and an option exercise. On May 29, 2026, Ndu exercised restricted stock units covering 8,107 shares of common stock, bringing direct common stock holdings to 32,908 shares.
Ndu also received 9,311 new restricted stock units and 16,004 director stock options with an exercise price of $21.66 per share. According to the footnotes, the 9,311 restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting, while the options vest quarterly over one year on a similar schedule. The filing shows compensation-related awards and conversions, with no open-market purchases or sales.
ACADIA PHARMACEUTICALS INC director Laura Brege reported equity compensation and option activity. She exercised 8,107 previously granted restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 23,202 shares.
On the same date, she received a new grant of 9,311 restricted stock units, each representing a right to one share of common stock, and a grant of 16,004 director stock options with an exercise price of $21.66 per share, expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting. Brege has elected to defer receipt of the shares underlying the new restricted stock units until specified future events such as a set anniversary date, ceasing board service, or a change in control under the company’s 2024 Equity Incentive Plan.
ACADIA PHARMACEUTICALS INC director Jonathan Poole reported equity compensation activity, including option exercises and new awards. He exercised derivative securities for 2,010 shares of common stock and now holds 2,010 common shares directly. He also received 9,311 restricted stock units and 16,004 director stock options.
The 9,311 restricted stock units each represent a right to one share of common stock and will vest in full on the earlier of one year from grant or the next annual stockholder meeting, with settlement deferred based on his election. The 16,004 stock options vest quarterly over one year following the grant date and have an exercise price of $21.66 per share.
ACADIA PHARMACEUTICALS director Elizabeth A. Garofalo reported equity compensation activity centered on RSUs and stock options. On May 29, 2026, she exercised 8,107 restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 33,489 shares.
She also received a new grant of 9,311 restricted stock units, each representing one future share of common stock, and 16,004 director stock options with a strike price of $21.66 per share that vest quarterly over one year. The new RSUs will vest in full on the earlier of one year from grant or the next annual meeting, and she has elected to defer receipt of the underlying shares until specified future triggers.
ACADIA PHARMACEUTICALS director James M. Daly reported equity compensation activity on May 29, 2026. He exercised previously granted restricted stock units, receiving 8,107 shares of common stock, and held 12,148 common shares directly after these transactions.
On the same date, he was granted 9,311 restricted stock units, each representing one share of common stock, and 16,004 director stock options with an exercise price of $21.66 per share expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units are scheduled to vest in full on the earlier of one year after grant or the next annual meeting, with Daly electing to defer receipt of the underlying shares under the company’s 2024 Equity Incentive Plan.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara sold 5,401 shares of common stock in an open-market sale at a weighted average price of $21.18 per share. After the transaction, he directly owns 24,509 shares, including 781 shares acquired on May 15, 2026 through an employee stock purchase plan.
ACADIA PHARMACEUTICALS principal accounting officer James Kihara exercised and vested equity awards and sold shares to cover taxes. On May 1, 2026, he exercised 2,596 restricted stock units, receiving the same number of common shares at $0.00 per share. On May 4, 2026, 1,332 common shares were sold at a weighted average price of $21.79, with footnotes stating these mandatory sales were solely to cover withholding taxes and tax-related items in connection with the RSU vesting and intended to meet Rule 10b5-1(c) requirements. After these transactions, he directly held 29,129 common shares.
ACADIA PHARMACEUTICALS INC EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On May 1, 2026, restricted stock units representing 6,815 shares of common stock vested and were exercised at $0.00 per share.
On May 4, 2026, 3,506 shares of common stock were sold in open-market transactions at a weighted average price of $21.79 per share to cover withholding taxes and tax-related items tied to this vesting, consistent with Rule 10b5-1(c) requirements. After these transactions, Schneyer directly held 66,145 shares of common stock.
ACADIA Pharmaceuticals EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On April 5, 5,276 restricted stock units were exercised into 5,276 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings. The restricted stock units vest in four equal annual installments beginning April 5, 2023.
On April 7, 2,709 shares of common stock were sold at $22.20 per share, leaving Schneyer with 62,836 shares directly owned after the transactions. According to the disclosure, these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c) under the Exchange Act.
ACADIA PHARMACEUTICALS’ principal accounting officer, James Kihara, reported routine RSU vesting and related tax sales. On April 5, 2026, 2,010 restricted stock units were converted into 2,010 shares of common stock at $0.00 per share. The same RSU grant vests in four equal annual installments beginning April 5, 2023.
On April 7, 2026, 1,030 of these shares were sold in open-market transactions at a weighted-average price of $22.20 per share, with actual prices ranging from $22.07 to $22.20. A footnote states these mandatory sales were made to cover withholding taxes and related tax items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c). After these transactions, Kihara directly holds 27,865 shares of Acadia common stock.
ACADIA PHARMACEUTICALS Chief Executive Officer Catherine Owen Adams reported routine equity transactions linked to restricted stock unit vesting. On March 24, 2026, she exercised 23,509 restricted stock units, receiving the same number of common shares at a $0.00 conversion price and increasing her direct common stock holdings to 26,444 shares.
On March 25, 2026, she made an open-market sale of 11,641 common shares at $21.47 per share. Footnotes state these mandatory sales were to cover withholding taxes and related items in connection with restricted stock unit vesting and are intended to comply with Rule 10b5-1(c). Following the sale, she directly holds 14,803 common shares and 70,530 restricted stock units, which vest in four equal annual installments beginning March 24, 2026.
ACADIA PHARMACEUTICALS executive vice president and chief legal officer Jennifer J. Rhodes exercised 7,515 restricted stock units into the same number of common shares at a conversion price of $0.00 per share. The next day, she sold 3,844 common shares at $21.47 per share.
According to the disclosure, these sales were mandatory and made solely to cover withholding taxes and related tax items tied to the RSU vesting, and are intended to comply with Rule 10b5-1(c). After the sale, Rhodes directly holds 11,280 common shares.
ACADIA Pharmaceuticals EVP Elizabeth H.Z. Thompson reported routine equity compensation activity. On March 24, 2026, she acquired 6,715 shares of common stock at $0.00 per share upon vesting of restricted stock units, increasing her direct holdings to 6,715 shares and 20,146 restricted stock units. On March 25, 2026, 3,435 shares were sold at $21.47 per share to cover withholding taxes and related items under a Rule 10b5-1 arrangement, leaving her with 3,280 common shares directly. The restricted stock units vest in four equal annual installments beginning March 24, 2026.
ACADIA PHARMACEUTICALS’ principal accounting officer, James Kihara, reported routine equity compensation activity and related share sales. He exercised or converted a total of 3,769 restricted stock units into common stock at a conversion price of $0.0000 per share, each unit representing one share of common stock.
Across March 24–26, 2026, he disposed of 1,942 shares of common stock in transactions coded as open‑market sales at prices between $21.47 and $21.7253 per share. A footnote explains these mandatory sales were made to cover withholding taxes and related tax items in connection with vesting of restricted stock units and were intended to meet Rule 10b5‑1(c) requirements. After these transactions, Kihara directly holds 26,885 shares of common stock and 4,883 restricted stock units that vest annually in four equal installments starting on March 24, 2026 and March 25, 2025.
ACADIA PHARMACEUTICALS EVP and CFO Mark C. Schneyer reported a combination of equity vesting and related share sales. On March 24 and 25, 2026, he exercised restricted stock units into a total of 14,316 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On March 25 and 26, 2026, he sold an aggregate 7,385 shares of common stock in open-market transactions at prices around $21.47–$21.72 per share. A footnote states these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1. Following these transactions, he directly holds 60,269 shares of common stock.
ACADIA PHARMACEUTICALS director Jonathan Poole received new equity awards as part of his compensation. On March 3, 2026, he was granted 7,482 director stock options with a $22.50 exercise price that vest in equal annual installments over three years, and 3,565 additional options at the same exercise price that vest quarterly over one year, with the final tranche vesting on the earlier of one year after grant or the next annual stockholder meeting. He was also granted 4,218 restricted stock units that vest in equal annual installments over three years and 2,010 restricted stock units that vest in full on the earlier of one year after grant or the next annual stockholder meeting. Each restricted stock unit represents the right to receive one share of common stock upon vesting.
ACADIA PHARMACEUTICALS INC reported equity awards to its Principal Accounting Officer, James Kihara. He received a stock option for 21,766 shares of common stock at an exercise price of $22.16 per share and 6,332 restricted stock units, both as compensation-related grants.
According to the terms, 25% of the option vests and becomes exercisable on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments after that date. The restricted stock units vest in four equal annual installments beginning March 6, 2027, each unit representing the right to receive one share of common stock. These are routine compensation awards, not open‑market purchases or sales.
ACADIA PHARMACEUTICALS INC executive Jennifer J. Rhodes, EVP and Chief Legal Officer, received new equity compensation awards. She was granted a stock option for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty‑five percent of this option vests on March 6, 2027, with the remainder vesting in 36 equal monthly installments thereafter. She also received 26,382 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are compensation grants and do not reflect any open‑market buying or selling.
ACADIA PHARMACEUTICALS INC reported that EVP and Chief Financial Officer Mark C. Schneyer received new equity awards. He was granted stock options for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. According to the terms, 25% of these options vest and become exercisable on March 6, 2027, with the remaining options vesting in 36 equal monthly installments thereafter.
Schneyer was also granted 26,382 restricted stock units, each representing a contingent right to receive one share of common stock. These restricted stock units vest in four equal annual installments beginning on March 6, 2027. All transactions are classified as awards or grants rather than open-market purchases or sales.
ACADIA PHARMACEUTICALS EVP and Chief Commercial Officer Thomas Garner reported compensation-related equity awards. He received stock options for 97,947 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty-five percent of these options vest on March 6, 2027, with the rest vesting in 36 equal monthly installments. He was also granted 28,493 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are awards from the company, not open-market purchases or sales.
ACADIA PHARMACEUTICALS INC executive Elizabeth H.Z. Thompson, EVP and Head of Research & Development, received new equity awards. She was granted a stock option for 101,574 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036.
According to the vesting terms, 25% of this option will vest and become exercisable on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. She also received 29,548 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning March 6, 2027.
ACADIA PHARMACEUTICALS INC reported that Chief Executive Officer Owen Adams Catherine received new equity awards. She was granted stock options for 263,005 shares of common stock at an exercise price of 22.1600, vesting 25% on March 6, 2027, with the remainder vesting in 36 equal monthly installments and expiring on March 5, 2036. She also received 76,509 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These awards are compensation grants and do not involve any open-market purchases or sales.
ACADIA Pharmaceuticals’ EVP and Chief Legal Officer Jennifer J. Rhodes reported equity transactions related to vested stock awards. On February 6, 2026, 12,944 restricted stock units were converted into common shares at an exercise price of $0, reflecting previously granted equity compensation.
On February 9, 2026, she sold 6,950 shares of common stock at a weighted average price of $23.38 per share in mandatory sales to cover withholding taxes and related items tied to the vesting. Following these transactions, she directly owned 7,609 shares of common stock and 12,945 restricted stock units, which continue to vest through February 2028.
ACADIA PHARMACEUTICALS INC (ACAD) executive vice president and chief financial officer reported equity transactions in company stock. On 11/17/2025, restricted stock units converted into 9,913 shares of common stock twice, increasing directly held shares. On 11/18/2025, the reporting person sold 10,262 shares of common stock at a weighted average price of $23.6907 per share, with sales made in multiple trades between $23.69 and $23.77. After these transactions, the reporting person directly beneficially owned 53,338 shares of common stock. The filing notes that certain sales were mandatory to cover withholding taxes related to restricted stock unit vesting and are intended to meet Rule 10b5-1(c) requirements. The restricted stock units generally vest over four years, with 37.5% vesting 18 months from grant, 12.5% on the second anniversary, and 25% on each of the third and fourth anniversaries, and some awards may vest earlier if the stock reaches a specified price over a set trading period.
ACADIA Pharmaceuticals (ACAD) principal accounting officer reported equity transactions involving company stock. On 11/17/2025, 3,966 restricted stock units converted into 3,966 shares of common stock at an exercise price of $0, twice, increasing directly held shares. On 11/18/2025, 4,084 shares of common stock were sold at a weighted average price of $23.6909 to cover withholding taxes and related items in connection with restricted stock unit vesting, under a Rule 10b5-1(c) plan. Following these transactions, the reporting person directly owned 25,058 shares of ACADIA common stock. Some restricted stock units feature a multi-year vesting schedule and may vest earlier if the stock reaches specified price targets over a set trading period.
ACADIA Pharmaceuticals (ACAD) director reported an open-market sale of 30,000 shares of common stock on 11/10/2025 at a weighted average price of $22.3661. The filing notes the trades occurred across multiple transactions within a range of $22.14 to $22.63. After the sale, the reporting person beneficially owns 4,041 shares, held directly.